

## Evaluation Report for Category B, Subcategory 3.11 Application

**Application Number:** 2023-6074  
**Application:** New or Changes to the Product Label – New Pests  
**Applicant:** Corteva AgriScience Canada Company  
**Product:** Garlon XRT Herbicide  
**Registration Number:** 28945  
**Active ingredient (a.i.):** 755 g/L triclopyr (present as butoxyethyl ester)  
**PMRA Document Number:** 3536238

### Purpose of Application

The purpose of this application was to include dog strangling vine as a weed controlled by an application of Garlon XRT Herbicide.

### Chemistry, Health and Environmental Assessment

Chemistry, health, and environmental assessments were not required as there was no change to product chemistry, product formulation, or use pattern.

### Value Assessment

The inclusion of dog strangling vine as a weed suppressed and controlled to on the Garlon XRT Herbicide label provides users with an additional option to manage this problematic, difficult to control invasive weed to protect native plants, bushes and trees natural habitats.

The applicant submitted value information that included reports of efficacy trials conducted between 2020 and 2022 in Ontario on dog strangling vine. Based on the results, Garlon XRT Herbicide applied at 2.5 and 5.0 L/ha, and in combination with the labelled rate of Gateway Adjuvant, can be expected to, respectively, suppress and control this weed in the year of and in the year following application.

### Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information acceptable to support the inclusion of dog strangling vine as a weed suppressed or controlled by Garlon XRT Herbicide applied as per label directions.

## References

- 3517710 2023, 10.2.3.3 DSV ARM, DACO: 10.2.3.3  
3517711 2023, DACO 10 - Garlon XRT - addition of Dog Strangling Vine, DACO: 10.1, 10.2, 10.2.1, 10.2.3, 10.2.3.1, 10.2.3.3(A), 10.3, 10.3.1, 10.3.3

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2024

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.